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Abstract
Background: The recent growing evidence that the proxi-
mal tubule underlies the early pathogenesis of diabetic kid-
ney disease (DKD) is unveiling novel and promising perspec-
tives. This pathophysiological concept links tubulointersti-
tial oxidative stress, inflammation, hypoxia, and fibrosis with 
the progression of DKD. In this new angle for DKD, the pre-
vailing molecular mechanisms on proximal tubular cells 
emerge as an innovative opportunity for prevention and 
management of DKD as well as to improve diabetic dys-
metabolism. Summary: The mercapturate pathway (MAP) is 
a classical metabolic detoxification route for xenobiotics 
that is emerging as an integrative circuitry detrimental to 
resolve tubular inflammation caused by endogenous elec-
trophilic species. Herein we review why and how it might 
underlie DKD. Key Messages: MAP is a hallmark of proximal 
tubular cell function, and cysteine-S-conjugates might rep-
resent targets for early intervention in DKD. Moreover, the 
biomonitoring of urinary mercapturates from metabolic in-
flammation products might be relevant for the implementa-
tion of preventive/management strategies in DKD.
© 2019 S. Karger AG, Basel
Proximal tubule underlies the early pathogenesis 
of diabetic kidney disease (DKD) [1]. The defined patho-
physiological tubulocentric concept of DKD identifies 
the unique early growth phenotype of the proximal tu-
bule as a potential target for the prevention of early tu-
bular hyperreabsorption and glomerular hyperfiltra-
tion, but perhaps more importantly, its early link to tu-
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bulointerstitial inflammation, fibrosis, oxidative stress, 
hypoxia, and kidney dysfunction [2]. The present review 
aims to include the mercapturate pathway (MAP) in the 
roadmap of tubulocentric concept of DKD.
The MAP Is a Hallmark of Proximal Tubular Cell 
Function
The MAP has been associated to chronic kidney dis-
ease (CKD) and is mainly expressed in renal proximal 
tubular cells [3–5], predominantly in cortical regions [3, 
6]. MAP was described as a metabolic detoxification cir-
cuitry for electrophilic species generated under inflam-
matory and oxidative conditions [7] (Fig. 1).
In fact, MAP enzymes have endogenous functions in 
the kidney and may have evolved to detoxify endogenous 
reactive toxic intermediates rather than only xenobiotics 
[8–10]. Endogenous compounds undergoing MAP in-
clude leukotrienes [6], glucose [11], catecholamines [12], 
cysteine-disulfides [13], and lipid peroxidation products 
[14, 15], whereas paracetamol [16] and cisplatin [17] are 
examples of xenobiotics.
Any cell under inflammatory or oxidative conditions 
can produce γ-glutamylcysteinylglycine (GSH) conju-
gates upon the intracellular conjugation of GSH with an 
electrophile, generating covalent glutathione-S-conju-
gates, also denominated as GSH-electrophile adducts 
(GSH-X) [18] (Fig. 1a). However, as cells are not able to 
catabolize these conjugates, they are excreted to the 
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Fig. 1. Mechanistic hypothesis of MAP role in the tubulocentric 
view of diabetic kidney disease (DKD) billed up on literature re-
view herein presented. (a) GSH-S-conjugates (GSH-X) of electro-
philes increase in inflammatory conditions in both immune and 
nonimmune cells, (b) being excreted into the bloodstream and 
have a short half-life due to its rapid (c) metabolization at the ex-
ternal apical membrane of proximal tubular cells. The generated 
cysteine-S-conjugate (Cys-X) may have one of 3 fates. (d) They 
may be detoxified by N-acetyltransferase 8 (NAT8), generating 
mercapturates that are eliminated in urine, (e) they may be bioac-
tivated to highly cytotoxic species or (f) they may be reabsorbed 
into the bloodstream, (g) perpetuating metabolic inflammatory 
processes and DKD progression.
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bloodstream (Fig. 1b). Their permanence in the blood-
stream is transitory [11, 19], as they undergo MAP 
(Fig. 1c). MAP is majorly expressed in proximal tubular 
cells of kidney cortex [3, 6] and includes 3 enzymes that 
act in consecutive steps. First, γ-glutamiltranspeptidase, 
that is the only enzyme known to initiate the breakdown 
of GSH-X, generates cysteinyl-glycine-S-conjugates. 
Those are cleaved by cysteinyl-glycine dipeptidase or, to 
a minor extent, aminopeptidase-M, to form cysteine-S-
conjugates (Cys-Xs). All ectoenzymes are majorly present 
at the brush border membrane of proximal tubular cells 
[3, 5, 20, 21]. However, the enzymes are also present in 
other tissues as liver, small intestine, lung, brain, spleen, 
and pancreas (for review see [22]), enabling Cys-X forma-
tion that can be delivered to the kidney by glomerular 
filtration [22]. 
The formed Cys-X has significantly higher half-life 
than the precursor and is the plausible responsible for bi-
ological effects [11, 19]. The effects of Cys-X have been 
underestimated, probably because MAP has been classi-
cally considered a detoxification route for xenobiotics. 
Although, it is known that cysteine-cisplatin is more tox-
ic to tubular cells than cisplatin [17]. Another example, 
the Cys-X of paracetamol is related to its nephrotoxicity, 
but not hepatotoxicity [23].
The information available regarding the precise trans-
porter involved in the entrance of Cys-Xs into tubular 
cells in man is, as far as we known, still to be identified. 
There is evidence in vitro and in animal models that Cys-
X enter the proximal tubular cells by sodium-dependent 
and independent transepithelial transport across both ba-
solateral and brush border membranes, including through 
organic anion transporters (for a review see [22]).
When Cys-X go into the proximal tubular cell [24], 
they may undergo into one of 3 fates. First, they can be a 
substrate for N-acetyltransferase 8 (NAT8) that is pre-
dominantly expressed in the microsomes [6], producing 
an N-acetylcysteine-S-conjugate also known as a mercap-
turate [6]. The N-acetyl moiety of mercapturates confers 
a polar, water-soluble, and anionic character, making 
them more prone to elimination in urine [6, 24] (Fig. 1d). 
Hence, urinary mercapturates of several xenobiotics have 
been used for biomonitoring purposes in environmental 
and occupational exposure [25]. Thereby, the generation 
of mercapturates is considered a feature of proximal tu-
bular cells [26, 27]. 
On the other hand, Cys-Xs in the proximal tubular cell 
might also undergo β-elimination through β-lyase activ-
ity, forming reactive intermediates that have been strong-
ly related to kidney injury [27, 28] (Fig. 1e). β-Lyases cat-
alyze the cleavage of Cys-X into a potentially toxic thiol 
(sulfur)-containing fragment and dehydroalanine, which 
very rapidly hydrolyzes to ammonia and pyruvate [22]. In 
rat, β-lyase is present mainly in cytosol and, to a lesser 
extent, in mitochondria. Differently, in man, a consider-
able β-lyase activity was found in microsomes. Studies 
performed in rat have shown that this activity is absent in 
the glomeruli and distal tubule. Regarding distribution in 
the proximal tubule, there are conflicting data on the seg-
ments involved [29, 30]. The involvement of β-lyase-
mediated bioactivation of Cys-X in nephrotoxicity has 
been demonstrated for several toxicants (for a review see 
[22] and [31]). 
In accordance, a nephroprotective role has been at-
tributed to the tubular enzyme NAT8 that promotes the 
urinary elimination of these compounds [6], counter-
acting β-lyase activity, avoiding their reabsorption into 
the bloodstream and promotion of systemic metabolic 
inflammation (Fig. 1f). Evidence supporting that NAT8 
is nephroprotective came majorly from association 
studies [3, 32–34]. The study of Juhanson et al. [32] in-
cluded 137 controls and 157 hypertensive patients with 
and without nephropathy and identified single-nucleo-
tide polymorphisms in the promoter region of NAT8 
associated with systolic blood pressure and renal func-
tion (estimated glomerular filtration rate [eGFR]). In 
particular, minor alleles (of the same single-nucleotide 
polymorphisms) were found to be related with lower 
blood pressure and higher eGFR. The authors hypoth-
esized that this effect was explained by the reduced sus-
ceptibility of the minor alleles to transcriptional sup-
pression, hence guarantying the availability of NAT8. 
Chambers et al. [3] reported an association between 
common genetic variations in NAT8 gene and creati-
nine, cystatin c, Egfr, and CKD in a population of 16,626 
Europeans. On the same year, the CKDGen consortium 
performed a meta-analysis of genome-wide association 
data in 67,093 Caucasian individuals and found that 
NAT8 was a susceptibility locus for reduced renal func-
tion, estimated by eGFR obtained separately with both 
creatinine and cystatin c and also CKD [34]. Moreover, 
NAT8 was the only kidney locus identified that was as-
sociated with eGFR in all 3 different genome-wide scans 
performed in 9,049 European Americans [33].
More recently, the role of NAT8 has been investigated 
in regenerative processes of the kidney tubular cell. Oma-
ta et al. [35] found a reduction of NAT8 transcript levels 
upon transforming growth factor-1 exposure using an in 
vitro model of dedifferentiation/reepithelization of hu-
man proximal tubular cells. This cytokine promoted cell 
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dedifferentiation, an event initiator of repair process in 
early stages of renal injury. Transforming growth factor-1 
withdrawing after dedifferentiation did not prevented 
reepithelization in NAT8 knock-down cells. The authors 
suggested that the recovery process may be independent 
of the activity of NAT8. In addition, the difficulty in de-
veloping NAT8 knockout rats [36] and absence of tools 
to pharmacologically address NAT8 hinders to get hard 
evidence on the nephroprotective role of this enzyme.
Cys-X have primarily vascular and hemodynamic 
properties [37], being potent vasoconstrictors [38–40] 
with an ability to enhance the permeability of the post-
capillary venules [41]. Therefore, the elimination of these 
conjugates could have nephroprotective consequences. 
It has been shown that Cys-Xs are involved in glucose-
stimulated insulin secretion [42] and have pro-inflamma-
tory [12], cytotoxic [17, 23, 43, 44], and immunogenic 
[45] properties (Fig. 1g), all processes involved in the de-
velopment of DKD.
Thus, MAP is a hallmark of proximal tubular cell func-
tion, and NAT8 activity is nephroprotective by avoiding 
systemic accumulation of Cys-Xs.
Cys-Xs Might Represent Targets for DKD
The formation of cysteinyl-leukotrienes (CysLTs) is 
the best described example among endogenous com-
pounds generated through MAP [6, 46]. CysLTs are 
products of arachidonic acid metabolism and key media-
tors of inflammatory conditions [47–49], which are re-
sponsible for enhancing the conversion of arachidonic 
acid into the short-lived LTA4 [50]. LTA4 is further con-
jugated with GSH to yield a glutathione-S-conjugate 
(LTC4) that is effluxed from cells. Extracellular LTC4 un-
dergoes a two-step catabolic process originating, respec-
tively, the cysteinyl-glycine-S-conjugate (LTD4) and 
Cys-X (LTE4) through the MAP [47, 48]. These com-
pounds are generally termed CysLTs, although these de-
nominations fully suit only for LTE4, which has the lon-
ger half-life [19]. DKD was associated with lower urinary 
LTE4 concentrations [51]. A multivariate analysis re-
vealed that only eGFR was an independent predictor of 
urinary LTE4 concentrations. Currently, there is no evi-
dence to support if this implicates a role for circulating 
LTE4 in its own urinary excretion, a decrease in its renal 
formation or an increase in its elimination as an N-acetyl-
LTE4 rather than in the LTE4 form.
As the best of the author’s knowledge, this association 
study was the only one investigating the effect of LTE4 in 
DKD. Although, there are descriptions in diabetes and 
kidney disease separately; for instance, the synthesis and 
release of CysLTs by the kidney have been described [44, 
52]. The role of leukotrienes in kidney diseases was re-
cently reviewed [53] and was demonstrated that they are 
able to reduce real blood flow and GFR by triggering va-
soconstriction. On the other hand, they can promote im-
mune and nonimmune-mediated kidney damage and ox-
idative intracellular stress [44]. The selective inhibition of 
CysLTs is being investigated in several models of kidney 
disease [53], but their nephroprotection ability in man is 
still unknown.
Under inflammatory conditions, the temporal chang-
es in urinary CysLTs elimination were paralleled with 
their biosynthesis enzyme activity in renal cortical micro-
somes. Urinary CysLTs levels increased in initial stages 
and decreased along kidney disease progression, support-
ing an early role for CysLTs in the development of subse-
quent functional changes [54]. 
CysLTs were reported to promote angiotensin II re-
lease, increase mean arterial pressure, decrease cardiac 
output, renal blood flow, and eGFR [55, 56]. Addition-
ally, several studies showed the association of CysLTs bio-
synthesis with drug-induced nephrotoxicity [53]. Lastly, 
in an in vitro approach, aristolochic acid I-induced tubu-
lar injury was associated with CysLTs release, via ERK 
pathway activation [57]. 
Regarding diabetes, it has been reported the effect of 
CysLTs as constrictors of the coronary vasculature in al-
loxan-diabetic rat [58, 59] and streptozotocin models, but 
not in fructose fed or insulin-treated diabetic animals [60, 
61]. On the other hand, the increased urinary excretion 
of LTE4 has been associated with diabetes [60, 62], sug-
gesting that hyperglycemia activates arachidonic acid 
metabolism and consequent CysLTs formation. Intensive 
glycemic control is able to reduce its elimination in pa-
tients with type 1 diabetes, although no changes were ob-
served in type 2 diabetes [60, 62, 63]. 
Glucose can also generate cysteinyl-S-conjugates that 
are far more stable than GSH-glucose and glucose-cyste-
ine urinary levels are higher in patients with diabetes 
[11]. 
Besides CysLTs and glucose-cysteine, another class of 
Cys-Xs is cysteine-disulfides. In a model of secondary hy-
pertension and insulin resistance, the levels of cysteine-
disulfides in kidney increased in early phases of disease 
[64].
While the available evidence is mainly focused on 
CysLTs, there are other endogenous Cys-Xs, which levels 
are changed in inflammatory conditions. Even though, 
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several aspects on CysLTs are missing such as their syn-
thesis and mechanism of action in immune and non-im-
mune-mediated kidney damage on diabetic milieu. Also, 
the receptor responsible for LTE4 effects is still to be clar-
ified [65]. The methodology employed for the quantifica-
tion of MAP S-conjugates should allow the discrimina-
tion between GSH-S-conjugates, Cys-Xs, and mercaptur-
ates in serum and urine and their relation with DKD. 
Urinary Mercapturates for Biomonitoring in DKD
Based on the association of NAT8 and kidney function 
[32], urinary mercapturates may be used as a hallmark of 
proximal tubular cells capability to detoxify Cys-X. This 
enzyme is highly and almost exclusively expressed in 
proximal tubular cells [3]. In addition, mercapturates are 
measured in urine, rendering them feasible for biomoni-
toring purposes [13, 25].
There has been an association between mercapturates 
of endogenous compounds and kidney disease. Decreased 
urinary levels of mercapturates of cysteine-disulfides 
were associated with kidney disease progression in HIV-
infected patients [13].
The urinary elimination of the mercapturate N-acetyl-
LTE4 is increased in inflammatory conditions [54] and 
with cyclosporine A treatment [66]. 
Acrolein is a dietary, environmental pollutant and lip-
id metabolism-derived electrophile associated to diabetic 
dysmetabolism and 2 of its urinary mercapturates were 
associated with diabetes and insulin resistance [15]. Uri-
nary acrolein mercapturates are increased in diabetic pa-
tients and are related to glycemic control parameters, but 
not with lipid metabolism nor albumin to creatinine ratio 
[67]. 
Another electrophile that undergoes the MAP is 4-hy-
droxynonenal (HNE), a normal constituent of mamma-
lian cell membranes, considered a highly potent reactive 
species that promotes propagation and amplification of 
the effects elicited by free radicals. The evaluation of HNE 
metabolism in vivo can be performed by monitoring uri-
nary HNE mercapturate that is decreased in patients with 
impaired glucose tolerance [14].
In summary, there is evidence on the biomonitoring of 
mercapturates of endogenous compounds in man and its 
relation to metabolic control in diabetes and also to kid-
ney disease. Although there are dozens of endogenous 
compounds undergoing MAP [46], information is still 
missing such as the contribution of each particular mer-
capturate in DKD.
Herein, we focused on Cys-X that have been associated 
to DKD, kidney disease, and/or diabetes. We found that 
LTE4, cysteinyl-glucose, and cysteine-disulfides have 
been associated to the pattern of Cys-X associated to these 
conditions. However, the literature review-driven hy-
pothesis herein built might not be exclusive for diabetes. 
For instance, LTE4 is known to be associated to DKD [51] 
and to other inflammatory diseases such as coronary ar-
tery disease [68], cardiac ischemia [69], asthma [70], as 
well as with obesity and hypoxia severity related to sleep 
apnea [71]. Even though, cysteinyl-glucose was only re-
ported in patients with diabetes [11], and on the basis that 
these compounds have in common the detoxification by 
the proximal tubular cells as mercapturates that might 
motivate a tubulocentric perspective for other inflamma-
tory conditions.
Summary and Perspectives in Mercapturate 
Involvement in DKD
The inability of proximal tubular cells to detoxify 
cysteinyl-S-conjugates, through NAT8 activity, might 
perpetuate metabolic inflammation and dysmetabo-
lism and supports that MAP underlies the tubulocentric 
perspective of DKD. This dysfunction in proximal tu-
bular cell activity can be monitored through the quan-
tification of mercapturates of cysteinyl-S-conjugates in 
urine. 
A better understanding of MAP impairment trigger-
ing early DKD is necessary. Such knowledge may help to 
find out new therapeutic approaches and strategies for 
early prediction and biomonitoring of DKD. 
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